Ultragenyx Outlines 2027 Profitability Strategy Following Pipeline Adjustments
Ultragenyx Pharmaceutical Inc. (RARE) has detailed a strategic roadmap to achieve profitability by 2027. The plan focuses on disciplined cost management, targeting Research and Development (R&D) expenses below $350 million and Selling, General, and Administrative (SG&A) costs under $375 million. The company's recent operational shifts include the discontinuation of its GTX-102 program alongside two significant FDA approvals for GENGLYCOS in August and September. These moves reflect a pivot toward optimizing the existing pipeline while streamlining the cost structure to ensure long-term financial stability.
Tickers: $RARE
Topics: earnings call FDA approval pipeline updates
Read the full article at Seeking Alpha
Part of the story Ultragenyx outlines 2027 profitability plan with R&D under $350M and SG&A under $375M following GTX-102 discontinuation (2 articles)